# US 2012/0252836 A1 · 1,3-Dioxanes and Their Uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252836 A1
- Document ID: US20120252836A1
- Status: Published application
- Kind: A1
- Application number: 13/526,110
- Filed: 2012-06-18
- Published: 2012-10-04
- Earliest claimed: 2007-02-01
- Assignees: Evolva SA
- Inventors: Alexandra Santana Sorensen; Jean-Phillippe Meyer; Peteris Alberts; Mainkar Prathama
- Web page: https://patentgrep.com/patent/US20120252836A1

## CPC

- C07D 319/06: not condensed with other rings
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/77: of oxiranes
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 319/08: condensed with carbocyclic rings or ring systems
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 407/04: directly linked by a ring-member-to-ring-member bond
- C07D 407/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 491/10: Spiro-condensed systems
- C07D 491/113: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.

## Claims

### Claim at position 1

1-5. (canceled)

### Claim 6

A compound of formula (IV):
wherein R1 is hydrogen;
R2 is a C3-30 cyclic or heterocyclic ring optionally substituted with one or more substituent;
X is CH, or N;
R5 is H, OH, alkoxy, alkyl, or halogen; and
n is 1 or 2.

### Claim at position 3

7-9. (canceled)

### Claim 10 (depends on 6)

The compound of claim 6, wherein R2 is a C3-30 cyclic or heterocyclic ring optionally substituted with one or more of hydroxyl, halogen, nitro, aryl, alkoxy or alkyl.

### Claim 11 (depends on 6)

The compound of claim 6, wherein R2 is acenaphthene, benzothiophene, chromanone, indole, julolidine, naphthalene, or quinolone, each of which is optionally substituted with one or more of hydroxyl, halogen, nitro, aryl, alkoxy or alkyl.

### Claim 12

(canceled)

### Claim 13 (depends on 6)

The compound of claim 6, wherein X is N.

### Claim 14 (depends on 6)

The compound of claim 6, wherein X is CH.

### Claim 15 (depends on 14)

The compound of claim 14, wherein X is NR8, where R8 is H, methyl, or phenyl.

### Claim 16

(canceled)

### Claim 17 (depends on 6)

The compound of claim 6, wherein R2 is a group of the formula:
each of which is optionally substituted with one or more of hydroxyl, halogen, nitro, aryl, alkoxy or alkyl.

### Claim at position 12

18-20. (canceled)

### Claim 21 (depends on 6)

A method of treating cancer comprising administration of a compound according to claim 6 to a subject in need of such treatment.

### Claim 22 (depends on 21)

The method of claim 21, wherein the subject is a domestic animal.

### Claim 23 (depends on 21)

The method of claim 21, wherein the subject is a human.

### Claim at position 16

24-39. (canceled)

### Claim 40 (depends on 6)

A method of treating tumor angiogenesis or metastasis in a cancer patient comprising administration of a compound according to claim 6 to the patient.

### Claim 41 (depends on 6)

A compound according to claim 6, wherein X is CH, and R2 is a group of the formula:
where R2a and R2b are independently hydrogen, hydroxyl, halogen, nitro, aryl, alkoxy or alkyl.

### Claim 42 (depends on 6)

A compound according to claim 6, which is
(Z)-6-(2-(6-Chloro-4-oxo-4H-chromen-3-yl)-4-(2-hydroxy phenyl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(2-(5-Chloro-1H-indol-3-yl)-4-(2-hydroxy phenyl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(2-(1,2-Dihydro acenaphthylen-5-yl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-((2R,4S,5R)-2-(8-hydroxy-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(2-(6,8-Dibromo-4-oxo-4H-chromen-3-yl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(2-(4,6-Dichloro-2H-chromen-3-yl)-4-(2-hydroxy phenyl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(2-(6,8-Dichloro-4-oxo-4H-chromen-3-yl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(4-(2-Hydroxy phenyl)-2-(6-nitro-4-oxo-4H-chromen-3-yl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(2-(6-Fluoro-4-oxo-4H-chromen-3-yl)-4-(2-hydroxy phenyl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(2-(2-Chloro-6-methyl quinolin-3-yl)-4-(2-hydroxy phenyl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(2-(3-Benzo[b]thiophen-2-yl)-4-(2-hydroxy phenyl-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-2-((3aR,4R,5R,6aS)-5-(Benzyloxy)-2-oxo-hexa hydro-2H-cyclopenta[b]furan-4-yl)-4-(2-hydroxy phenyl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(2-(2-(4-Fluoro phenyl)-1H-indol-3-yl)-4-(2-hydroxy phenyl)-1,3-dioxan-5-yl)-hex-4-enoic acid;
(Z)-6-(4-(2-Hydroxy phenyl)-2-(1-methyl-1H-indol-3-yl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(2-(6-Chloro-4-oxo-4H-chromen-3-yl)-4-(pyridine-3-yl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(Z)-6-(2-(1H)-Benzo[d][1,2,3]triazol-1-yl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl)hex-4-enoic acid;
(E)-3-(6-Chloro-4-oxo-4H-chromen-3-yl)-4-(2-hydroxy phenyl)-1,3-dioxan-5-yl)acrylic acid; or
a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 6)

A compound according to claim 6, which is
or a pharmaceutically acceptable salt thereof.
